Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its price target decreased by equities researchers at Needham & Company LLC from $55.00 to $52.00 in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 57.34% from the stock’s current price.

Several other research firms have also recently issued reports on PCRX. Wedbush reissued an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 23rd. Mizuho reissued a “buy” rating and issued a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. ValuEngine cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Cowen and Company reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $51.86.

Shares of Pacira Pharmaceuticals (PCRX) opened at 33.05 on Thursday. The firm’s market cap is $1.33 billion. Pacira Pharmaceuticals has a 12-month low of $29.95 and a 12-month high of $58.95. The firm has a 50-day moving average price of $36.60 and a 200-day moving average price of $42.58.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. During the same period in the previous year, the company posted $0.21 EPS. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts expect that Pacira Pharmaceuticals will post ($0.19) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) PT Lowered to $52.00” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/19/pacira-pharmaceuticals-inc-pcrx-pt-lowered-to-52-00.html.

In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total value of $127,191.75. Following the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 5.2% during the second quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after purchasing an additional 270 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after purchasing an additional 303 shares during the last quarter. Denver Investment Advisors LLC lifted its holdings in shares of Pacira Pharmaceuticals by 6.8% during the second quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after purchasing an additional 435 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Pacira Pharmaceuticals by 12.7% during the second quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after purchasing an additional 566 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.